Lindsay R. Berry
A5107411260- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Sepsis Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Venous Thromboembolism Diagnosis and Management
- Forecasting Techniques and Applications
- Statistical Methods in Clinical Trials
- Intensive Care Unit Cognitive Disorders
- Cancer Treatment and Pharmacology
- Respiratory Support and Mechanisms
- COVID-19 and Mental Health
- Innovation Diffusion and Forecasting
- Biosimilars and Bioanalytical Methods
- Thermal Regulation in Medicine
- COVID-19 and healthcare impacts
- Mechanical Circulatory Support Devices
- Vitamin C and Antioxidants Research
- Heart Failure Treatment and Management
- Optimal Experimental Design Methods
- Nausea and vomiting management
- Cancer Genomics and Diagnostics
- Infection Control in Healthcare
- Statistical Methods and Bayesian Inference
- Advanced Breast Cancer Therapies
- Muscle and Compartmental Disorders
Berry & Associates (United States)
2018-2025
Association Clinique et Thérapeutique Infantile du Val de Marne
2023
Medical Research Institute of New Zealand
2023
University of Auckland
2023
Middlemore Hospital
2023
Auckland City Hospital
2023
University Health Network
2021
St. Michael's Hospital
2021
Health Sciences Centre
2021
Sunnybrook Health Science Centre
2021
The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.We evaluated tocilizumab and sarilumab an ongoing international, multifactorial, adaptive platform trial. Adult Covid-19, within 24 hours after starting organ support the intensive care unit (ICU), were randomly assigned to receive (8 mg per kilogram body weight), (400 mg), or standard (control). primary outcome was respiratory cardiovascular support-free days, on...
Thrombosis and inflammation may contribute to morbidity mortality among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill Covid-19.
<h3>Importance</h3> Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. <h3>Objective</h3> To determine whether hydrocortisone improves outcome patients with COVID-19. <h3>Design, Setting, and Participants</h3> An ongoing adaptive platform trial testing multiple interventions within therapeutic domains, example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 June 17, 2020, 614 adult suspected confirmed COVID-19 were enrolled...
Thrombosis and inflammation may contribute to the risk of death complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized that therapeutic-dose anticoagulation improve outcomes in noncritically ill who are hospitalized Covid-19.In this open-label, adaptive, multiplatform, controlled trial, we randomly assigned were Covid-19 not critically (which was defined as an absence critical care-level organ support at enrollment) receive pragmatically regimens either...
Abstract Background The efficacy of interleukin-6 receptor antagonists in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear. Methods We evaluated tocilizumab and sarilumab an ongoing international, multifactorial, adaptive platform trial. Adult Covid-19, within 24 hours commencing organ support intensive care unit, were randomized to receive either (8mg/kg) or (400mg) standard (control). primary outcome was ordinal scale combining in-hospital mortality (assigned −1)...
Importance Randomized clinical trials (RCTs) of therapeutic-dose heparin in patients hospitalized with COVID-19 produced conflicting results, possibly due to heterogeneity treatment effect (HTE) across individuals. Better understanding HTE could facilitate individualized decision-making. Objective To evaluate for and compare approaches assessing HTE. Design, Setting, Participants Exploratory analysis a multiplatform adaptive RCT vs usual care pharmacologic thromboprophylaxis 3320 enrolled...
<h3>Importance</h3> The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-CoV-2 Delta variant. <h3>Objective</h3> To evaluate mAb against variant compared no treatment ascertain comparative sotrovimab. <h3>Design, Setting, Participants</h3> This study comprised 2 parallel studies: (1) a propensity score–matched cohort vs (2) randomized trial consisted who received at University...
The efficacy of simvastatin in critically ill patients with coronavirus disease 2019 (Covid-19) is unclear.
Lindsay R. Berrya & Mike Westba Berry Consultants LLC, 3345 Bee Caves Road, Suite 201, Austin, TX 78746 (); b Department of Statistical Science, Duke University, Durham, NC 27708 ()
<h3>Importance</h3> Monoclonal antibody (mAb) treatment decreases hospitalization and death in high-risk outpatients with mild to moderate COVID-19; however, only intravenous administration has been evaluated randomized clinical trials of treatment. Subcutaneous may expand outpatient capacity qualified staff available administer treatment, but the association patient outcomes is understudied. <h3>Objectives</h3> To evaluate whether subcutaneous casirivimab imdevimab associated reduced 28-day...
749 Background: The long-term survival rates for metastatic pancreatic cancer have remained stubbornly low decades. Most cancers dense, fibrous stroma tissue surrounding their tumors, which contributes to tumor growth and acts as a barrier many therapies. Nanomedicines been developed use in oncology reduce toxicity improve efficacy, but majority are too large (> 100nm) effectively penetrate dense stroma. DUO-207 is novel ultrasmall nanomedicine (~ 20nm) composed of copolymer-conjugated...
Rationale: Randomised clinical trials in intensive care often prioritize disease-focused outcomes rather than patient-centred outcomes. Objective: To report and evaluate the 'Daily Organ Support for patients on extracorporeal membrane oxygenation (ECMO)', DOSE outcome. This is a new longitudinal ordinal outcome receiving ECMO. Methods: Prospective, multicentre study 28 hospitals Australia New Zealand. Adult admitted to participating ICU between February 2019 September 2023 who underwent any...
Many trial designs, such as dose-finding trials, shared-control or adaptive platform investigate multiple therapies simultaneously. Often these trials seek to identify the best arm and compare it a control. Adaptive are commonly considered in this space, focusing on methods that drop arms adjust allocation response accumulating information. These continue be compared literature, most recently with an emphasis effect of time trends during experiment. Here we several methods, considering their...
Abstract Background Thrombo-inflammation may contribute to morbidity and mortality in Covid-19. We hypothesized that therapeutic-dose anticoagulation improve outcomes non-critically ill patients hospitalized for Methods In an open-label adaptive multiplatform randomized controlled trial, Covid-19, defined by the absence of critical care-level organ support at enrollment, were a pragmatic strategy with heparin or usual care pharmacological thromboprophylaxis. The primary outcome combined...
Abstract IMPORTANCE The effectiveness of monoclonal antibodies (mAbs), casirivimab and imdevimab, sotrovimab, for patients with mild to moderate COVID-19 from the Delta variant is unknown. OBJECTIVE To evaluate mAbs compared no treatment, comparative between mAbs. DESIGN, SETTING, AND PARTICIPANTS Two parallel studies among who met Emergency Use Authorization criteria July 14, 2021 September 29, 2021: i.) prospective observational cohort study comparing mAb treatment and, ii.) Bayesian...
ABSTRACT Background Neutralizing monoclonal antibodies (mAb) targeting SARS-CoV-2 decrease hospitalization and death in patients with mild to moderate Covid-19. Yet, their clinical use is limited, comparative effectiveness unknown. Methods We present the first results of an ongoing, learning health system adaptive platform trial expand mAb treatment all eligible evaluate available mAbs. The launched March 10, 2021. Results are reported as June 25, 2021 due U.S. federal decision pause...
Summary This paper describes a case of influenza A infection complicated by rhabdomyolysis and acute renal failure. very rare complication is particularly important as symptoms may be non-specific therefore ascribed to the underlying influenzal illness.
Introduction Implementation of enhanced recovery pathways (ERPs) has resulted in improved patient-centred outcomes and decreased costs. However, there is a lack high-level evidence for many ERP elements. We have designed randomised, embedded, multifactorial, adaptive platform perioperative medicine (REMAP Periop) trial to evaluate the effectiveness several therapies patients undergoing complex abdominal surgery as part an ERP. This will begin with two domains: postoperative nausea/vomiting...